Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Prospective, Open-label, Single-arm, Phase I-II Clinical Trial to Analyze Induction Therapy With a Combination of Fludarabine, Idarubicin, Cytarabine, G-CSF and Plerixafor for the Treatment of Young Patients With Relapsed or Refractory AML

NCT01435343 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT01435343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01435343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Prospective, Open-label, Single-arm, Phase I-II Clinical Trial to Analyze Induction Therapy With a Combination of Fludarabine, Idarubicin, Cytarabine, G-CSF and Plerixafor for the Treatment of Young Patients With Relapsed or Refractory AML
Lead sponsor
PETHEMA Foundation
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2012
Completion date
December 31, 2016
Enrollment
55 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloblastic leukemia